US EditionAstraZeneca Shifts Focus, Exits Neuroscience to Strengthen Core Therapeutic Areas
Summary by healtheconomics.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
AstraZeneca Shifts Focus, Exits Neuroscience to Strengthen Core Therapeutic Areas
AstraZeneca has decided to exit its neuroscience research efforts, discontinuing experimental drugs for Alzheimer’s, migraine, and pain to focus its resources on high-value projects within its core therapeutic areas such as cancer, cardiovascular, and respiratory diseases. This move aligns with AstraZeneca’s strategic goal of reaching $80 billion in annual revenue and launching 20 new drugs by 2030. The company’s decision reflects a broader indu…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
